Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 716-728

  Migden, Michael R ^a   Guminski, Alexander ^b   Gutzmer, Ralf ^c   Dirix, Luc ^d   Lewis, Karl D ^e   Combemale, Patrick ^f   Herd, Robert M ^g   Kudchadkar, Ragini ^h   Trefzer, Uwe ⁱ   Gogov, Sven ^j   Pallaud, Celine ^j   Yi, Tingting ^j   Mone, Manisha ^j   Kaatz, Martin ^k,l   Loquai, Carmen ^m   Stratigos, Alexander J ⁿ   Schulze, Hans Joachim ^o   Plummer, Ruth ^p   Chang, Anne Lynn S ^q   Cornélis, Frank ^r   Lear, John T ^s   Sellami, Dalila ^j   Dummer, Reinhard ^t   more..

^a University of Texas Health Science Center at Houston   (United States)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f Department of Onco Dermatology Anticancer Institute   (France)

^g GLASGOW ROYAL INFIRMARY   (United Kingdom)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ Dermatologikum Berlin   (Germany)

^j NOVARTIS PHARMA AG   (Switzerland)

^k JENA UNIVERSITY HOSPITAL   (Germany)

^l SRH Wald Klinikum Gera   (Germany)

^m UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁿ UNIVERSITY OF ATHENS   (Greece)

^o Fachklinik Hornheide   (Germany)

^p FREEMAN HOSPITAL   (United Kingdom)

^q STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^s UNIVERSITY OF MANCHESTER   (United Kingdom)

^t UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; MYOGLOBIN; SONIDEGIB; TRIACYLGLYCEROL LIPASE; BIPHENYL DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; ATRIAL FIBRILLATION; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGEUSIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SKIN METASTASIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; CARCINOMA, BASAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIPHENYL COMPOUNDS; CARCINOMA, BASAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84930273662     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70100-2     Document Type: Article

References (29)

1. Epstein EH Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008, 8:743-754.
2. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14:78-81.
3. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005, 152:43-51.
4. NCCN clinical practice guidelines in oncology. Basal cell skin cancer. V2 National Comprehensive Cancer Network, (accessed Nov 7, 2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nmsc.
5. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol 2013, 25:218-223.
6. Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014, 24:312-329.
7. Clinical practice guide. Basal cell carcinoma, squamous cell carcinoma (and related lesions) - a guide to clinical management in Australia Cancer Council Australia/Australian Cancer Network 2008, (accessed Nov 7, 2014). http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-Final_with_Corrigendums.pdf.
8. Dreier J, Dummer R, Felderer L, Nageli M, Gobbi S, Kunstfeld R Emerging drugs and combination strategies for basal cell carcinoma. Expert Opin Emerg Drugs 2014, 19:353-365.
9. Erivedge (vismodegib) package insert 2012, Genentech USA, San Francisco, CA.
10. CHMP summary of opinion for Erivedge European Medicines Agency, (accessed Nov 7, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002602/WC500142522.pdf.
11. Department of Health: Therapeutic Goods Administration. Australian public assessment report for vismodegib Australian Government, (accessed Nov 7, 2014). http://www.tga.gov.au/auspar/auspar-vismodegib.
12. Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010, 1:130-134.
13. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010, 2:51ra70.
14. Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 2014, 20:1900-1909.
15. WHO handbook for reporting results for cancer treatment 1979, WHO, World Health Organization, Geneva.
16. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
17. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
18. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999, 17:1008-1019.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 US Department of Health and Human Services, (accessed April 14, 2015). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
20. McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014, 50:774-783.
21. Pricl S, Cortelazzi B, Dal Col V, et al. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol 2015, 9:389-397.
22. Brinkhuizen T, Reinders MG, van Geel M, et al. Acquired resistance to the hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol 2014, 71:1005-1008.
23. Lorusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor GDC-0449 in patients with refractory, locally-advanced or metastatic solid tumors. Clin Cancer Res 2011, 17:2502-2511.
24. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366:2171-2179.
25. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 2014, 70:60-69.
26. Italiano A, Le Cesne A, Bellera C, et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol 2013, 24:2922-2926.
27. Lear JT Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med 2012, 366:2225-2226.
28. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol 2014, 71:904-911.
29. Mathias SD, Chren MM, Colwell HH, et al. Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires. JAMA Dermatol 2014, 150:169-176.